Skip to content
Article Rich – Lifestyle
Author:
Siren Biotechnology, Inc.
Siren Biotechnology Publishes Foundational AAV Immuno-Gene Therapy Data and Announces Presentations at ASGCT 2026
April 27, 2026
Siren Biotechnology Announces FDA Clearance of Investigator-Initiated IND to Advance Phase 1 Study in Recurrent High-Grade Glioma
March 23, 2026
Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma
March 4, 2026